GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
Whether an RNS at 0700 or an RNS out of hours, they'd both be before the summit, the only difference is that out of hours for the reason you've given could be construed as an intentional delay, therefore breaking AIM rules. If you're proposing we may get an RNS just before the summit presentation at 2145 UK time on Friday? Probably not. Dr. Jason Comander is presenting, so he'll only be able to convey results rather than a ReNeuron-specific update. Delaying a release is of no benefit to ReNeuron, and they seem quite on-board with releasing market-sensitive information in a timely manner since a small balls up a number of years ago. Regardless, a positive RNS will have a more immediate reach than a Friday afternoon summit presentation.
'An AIM company must issue notification without delay of any new developments which are not public knowledge which, if made public, would be likely to lead to a significant movement in the price of its AIM securities.' I'd suggest that releasing an RNS after trading hours but before the Summit starts would be an intentional delay. I also don't see any reason for doing it.
To clarify, $425,000 is the per-eye treatment cost for Spark's Luxturna, not for ReNeuron's hRPC line. Analyst per-eye treatment costs for hRPC seem to have reduced from $50,000 (EU) to $100,000 (US/Japan), to $35,000 (EU) to $50,000 (US/Japan).
'ReNeuron will also receive tiered royalties at rates between 12% and 14% on SALES of the licensed products in the Chinese market.' What do you mean they don't need ReNeuron? You think they're going to steal ReNeuron's technology and halt royalty payments?
Jaytee, the other reason it dropped over the years is dilutive funding, and the fear of further dilution. That is either close to being a thing of the past, or all these positive updates are an effort to drive the price up prior to further dilution...
It wasn't being run in a way that would generate significant interest, more like a university project. It had, until recently, been valued at less than cash reserves for quite some time. But in a relatively lean manner, albeit slowly, they've developed promising technologies and hold many patents. Clinical trials are showing positive results where there is currently very limited or no competition. Potential value if products get to market is many multiples higher than the current £50 million valuation. 100,000 RP patients in the US, even if only one eye treated, at £10,000 per eye for treatment that's £1 billion in sales just for a single product. 1 in 4,000 people suffer with RP. And it may also help in cone rod dystrophy, and then there's the stroke therapy, and exosomes...
You assume an institution was buying, but amongst other things, it could be an individual (as was the case in March) or it could be a pharma company or multiples of either. An RNS would come when the 3% threshold has been passed, or a 1% change in either direction by a holder already in possession of >3%, not necessarily when they've finished buying or selling.